GLP1R and type 2 diabetes mellitus: Lixisenatide was approved in 2013 and 2016 by the EMA and the FDA, respectively, as the first once-daily injectable GLP-1 receptor agonist for the treatment of diabetes type II, presenting a half-life of ~3 h (Elkinson and Keating, 2013; Lorenz et al., 2013; US Food and Drug Administration, 2016).